Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/28965955/ below:

Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study

Affiliations

• ¹ University of Strathclyde, Glasgow, UK. Electronic address: kim.kavanagh@strath.ac.uk.
• ² Health Protection Scotland, Glasgow, UK.
• ³ Scottish Human Papillomavirus Reference Laboratory, Royal Infirmary of Edinburgh, UK.
• ⁴ University of Edinburgh, Edinburgh, UK; Department of Pathology, University of Edinburgh, UK.
• ⁵ University of Edinburgh, Edinburgh, UK.
• ⁶ University of Aberdeen, Aberdeen, UK.
• ⁷ University of Strathclyde, Glasgow, UK; Health Protection Scotland, Glasgow, UK; International Prevention Research Institute, Lyon, France.

• PMID: 28965955
• DOI: 10.1016/S1473-3099(17)30468-1

Item in Clipboard

Kimberley Kavanagh et al. Lancet Infect Dis. 2017 Dec.

• ¹ University of Strathclyde, Glasgow, UK. Electronic address: kim.kavanagh@strath.ac.uk.
• ² Health Protection Scotland, Glasgow, UK.
• ³ Scottish Human Papillomavirus Reference Laboratory, Royal Infirmary of Edinburgh, UK.
• ⁴ University of Edinburgh, Edinburgh, UK; Department of Pathology, University of Edinburgh, UK.
• ⁵ University of Edinburgh, Edinburgh, UK.
• ⁶ University of Aberdeen, Aberdeen, UK.
• ⁷ University of Strathclyde, Glasgow, UK; Health Protection Scotland, Glasgow, UK; International Prevention Research Institute, Lyon, France.

• PMID: 28965955
• DOI: 10.1016/S1473-3099(17)30468-1

Item in Clipboard

Background: On Sept 1, 2008, Scotland launched routine vaccination for human papillomavirus (HPV) types 16 and 18, targeted at 12-13-year-old girls, of whom 92·4% were fully vaccinated in 2008-09. In this study, we report on vaccine effectiveness of the bivalent vaccine in these vaccinated women who attended for routine cervical screening at age 20-21 years.

Methods: In this 7-year cross-sectional study (covering birth cohorts 1988-1995), we sampled approximately 1000 samples per year from those attending cervical screening at age 20-21 years and tested each for HPV. By linkage to vaccination records we ascertained prevalence by birth cohort and vaccination status. Estimates of vaccine effectiveness for HPV types 16 and 18, HPV types 31, 33, and 45, other high-risk types, and any HPV were calculated using logistic regression.

Findings: In total, 8584 samples were HPV genotyped. Prevalence of HPV types 16 and 18 reduced substantially from 30·0% (95% CI 26·9-33·1) in the 1988 cohort to 4·5% (3·5-5·7) in the 1995 cohort, giving a vaccine effectiveness of 89·1% (85·1-92·3) for those vaccinated at age 12-13 years. All cross-protective types showed significant vaccine effectiveness (HPV type 31, 93·8% [95% CI 83·8-98·5]; HPV type 33, 79·1% [64·2-89·0]; HPV type 45, 82·6% [61·5-93·9]). Unvaccinated individuals born in 1995 had a reduced odds of HPV types 16 and 18 infection compared with those born in 1988 (adjusted odds ratio 0·13 [95% CI 0·06-0·28]) and reduced odds of HPV types 31, 33, and 45 (odds ratio 0·45 [0·23-0·89]).

Interpretation: Bivalent vaccination has led to a startling reduction in vaccine and cross-protective HPV types 7 years after vaccination. There is also evidence of herd protection against the vaccine-specific and cross-protective types in unvaccinated individuals born in 1995. These findings should be considered in cost-effectiveness models informing vaccine choice and models to shape the future of cervical screening programmes.

Funding: Scottish Government and Chief Scientists Office.

Copyright © 2017 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

• Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.

  Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, McNamee K, Garefalakis M, Phillips S, Cummins E, Malloy M, Garland SM. Tabrizi SN, et al. Lancet Infect Dis. 2014 Oct;14(10):958-66. doi: 10.1016/S1473-3099(14)70841-2. Epub 2014 Aug 5. Lancet Infect Dis. 2014. PMID: 25107680

• Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.

  Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, Cruickshank M. Palmer T, et al. BMJ. 2019 Apr 3;365:l1161. doi: 10.1136/bmj.l1161. BMJ. 2019. PMID: 30944092 Free PMC article.

• Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.

  Chow EP, Danielewski JA, Fehler G, Tabrizi SN, Law MG, Bradshaw CS, Garland SM, Chen MY, Fairley CK. Chow EP, et al. Lancet Infect Dis. 2015 Nov;15(11):1314-23. doi: 10.1016/S1473-3099(15)00055-9. Epub 2015 Jul 19. Lancet Infect Dis. 2015. PMID: 26201300

• Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease.

  Cameron RL, Palmer TJ, Cuschieri K, Kavanagh K, Roy K. Cameron RL, et al. Vaccine. 2024 Aug 30;42(21):126177. doi: 10.1016/j.vaccine.2024.126177. Epub 2024 Aug 10. Vaccine. 2024. PMID: 39128198 Review.

• Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.

  Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Malagón T, et al. Lancet Infect Dis. 2012 Oct;12(10):781-9. doi: 10.1016/S1473-3099(12)70187-1. Epub 2012 Aug 22. Lancet Infect Dis. 2012. PMID: 22920953 Review.

• Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.

  Gray P, Kann H, Pimenoff VN, Eriksson T, Luostarinen T, Vänskä S, Surcel HM, Faust H, Dillner J, Lehtinen M. Gray P, et al. PLoS Med. 2021 Jun 7;18(6):e1003588. doi: 10.1371/journal.pmed.1003588. eCollection 2021 Jun. PLoS Med. 2021. PMID: 34097688 Free PMC article.

• Prevalence and Subtype Distribution of High-Risk Human Papillomavirus Among Women Presenting for Cervical Cancer Screening at Karanda Mission Hospital.

  Thistle P, Parpia R, Pain D, Lee H, Manasa J, Schnipper LE. Thistle P, et al. JCO Glob Oncol. 2020 Aug;6:1276-1281. doi: 10.1200/GO.20.00286. JCO Glob Oncol. 2020. PMID: 32783640 Free PMC article.

• Monitoring HPV vaccine impact on cervical disease: Status and future directions for the era of cervical cancer elimination.

  Oliveira CR, Niccolai LM. Oliveira CR, et al. Prev Med. 2021 Mar;144:106363. doi: 10.1016/j.ypmed.2020.106363. Epub 2021 Mar 4. Prev Med. 2021. PMID: 33678234 Free PMC article.

• Small Molecule Inhibitors of Human Papillomavirus: A Review of Research from 1997 to 2021.

  Duncan CL, Gunosewoyo H, Mocerino M, Payne AD. Duncan CL, et al. Curr Med Chem. 2024;31(33):5308-5350. doi: 10.2174/0929867331666230713165407. Curr Med Chem. 2024. PMID: 37448363 Review.

• Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied.

  Vänskä S, Luostarinen T, Baussano I, Apter D, Eriksson T, Natunen K, Nieminen P, Paavonen J, Pimenoff VN, Pukkala E, Söderlund-Strand A, Dubin G, Garnett G, Dillner J, Lehtinen M. Vänskä S, et al. J Infect Dis. 2020 Aug 17;222(6):948-956. doi: 10.1093/infdis/jiaa099. J Infect Dis. 2020. PMID: 32161969 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3